Amarin is a late-stage biopharmaceutical company with a focus on cardiovascular disease. The Companys lead product candidate is AMR101, a prescription grade Omega-3 fatty acid comprising not less than 96% ultra-pure ethyl eicosapentaenoic acid (EPA), which is entering Phase 3 clinical trials for the treatment of hypertriglyceridemia under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA). Amarin has a range of clinical and preclinical stage compound...Show all

Amarin is a late-stage biopharmaceutical company with a focus on cardiovascular disease. The Companys lead product candidate is AMR101, a prescription grade Omega-3 fatty acid comprising not less than 96% ultra-pure ethyl eicosapentaenoic acid (EPA),...Show all

See All Exits Recent Exits

Phone: 860-572-4979

Fax:

12 Roosevelt Avenue
Shelbourne Road Ballsbridge
Mystic, 06355
Connecticut, United States

Amarin - Investments & Acquisitions

Show Real Data
See all Recent Investments
Date Company Round Amount Co-investors
2008-08-15WeAre.UsSeed$0.05MDr. Declan Doogan
2007-12-06Ester NeurosciencesAcquired
See all 2 investments